Anti-PMCH polyclonal used in Amyotrophic Lateral Sclerosis research

May 2023 (Université de Strasbourg, INSERM, Mécanismes centraux et périphériques de la neurodégénérescence, UMR-S1118, Strasbourg, France)

Can we improve Metabolic Dysfunctions in Patients with Amyotrophic Lateral Sclerosis?

People living with Amyotrophic Lateral Sclerosis (ALS) burn more calories because of the increased energy spent on breathing, moving, and muscle twitching. Clinically, this increase in energy expenditure and decline in body mass index predicts a worse outcome.

Neural mechanisms underlying metabolic impairment in ALS remain unknown.

๐Ÿ‘‰ This study identifies impairment of hypothalamic melanin-concentrating hormone (MCH) neurons as contributors to inadequate food intake in ALS and proposes them as a new target for combatting ALS-induced deficits in energy metabolism.

Read the full article:

๐Ÿ”ฌThe study features our anti-PMCH (pro-melanin-concentrating hormone) rabbit polyclonal (HPA046055) used in immunohistochemistry on tissue from ALS patients. Image shows loss of hypothalamic MCH neurons in ASL.